ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 187,65
0,69%
Dow Jones
39 387,76
0,85%
DAX
18 686,60
1,07%
Brent Oil
84,155
0,24%
Bitcoin
62 781,90
-0,42%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Imunon Inc (IMNN)

  7. Imunon Inc (IMNN) Actualités

IMNN Imunon Inc

1,51
0,01 (0,67%)
09 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Imunon Inc IMNN NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,01 0,67% 1,51 23:59:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,53 1,43 1,57 1,51 1,50
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
08/5/202414:15EDGAR2Form 8-K - Current report
08/5/202414:00GLOBEIMUNON Appoints Director Dr. Stacy R. Lindborg as President..
06/5/202417:00GLOBEIMUNON to Hold First Quarter 2024 Financial Results and..
18/4/202414:30GLOBEIMUNON’s IND Application Cleared to Begin Human Testing of..
11/4/202414:00GLOBEIMUNON Reports Compliance with Nasdaq Listing Requirements
28/3/202413:00GLOBEIMUNON Reports 2023 Financial Results and Provides Business..
25/3/202413:30GLOBEIMUNON Receives $1.3 Million from Sale of its New Jersey Net..
21/3/202422:00GLOBEIMUNON to Hold 2023 Financial Results and Business Update..
13/3/202413:00GLOBEIMUNON Files IND Application to Begin Human Testing of..
12/3/202422:00GLOBEIMUNON Announces Leadership Change
29/2/202414:30GLOBEIndependent Lab Confirms Immunogenicity and Protection with..
27/2/202414:30GLOBEMemorial Sloan Kettering Cancer Center Now Enrolling..
22/2/202414:00GLOBEIMNN-101 Preclinical Data in SARS CoV-2 Published in..
09/2/202422:09EDGAR2Form S-1/A - General form for registration of securities..
29/12/202322:30EDGAR2Form 8-K - Current report
20/12/202323:15EDGAR2Form S-1 - General form for registration of securities under..
11/12/202322:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202322:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
11/12/202314:35EDGAR2Form 8-K - Current report
11/12/202314:30GLOBEIMUNON Appoints Dr. Sebastien Hazard as Chief Medical..
14/11/202315:00GLOBEIMUNON’s VP of R&D to Present at the Vaccines Summit-2023
14/11/202314:00GLOBEIMUNON Reports Third Quarter 2023 Financial Results and..
07/11/202314:30GLOBEIMUNON to Hold Third Quarter 2023 Financial Results and..
23/10/202314:30GLOBEIMUNON’s Chief Science Officer to Present at the 3rd..
19/10/202314:30GLOBEIMUNON CEO Dr. Corinne Le Goff to Participate in a Panel..
18/10/202314:30GLOBEIMUNON Announces First Patient enrolled in Phase 1/2..
06/10/202314:30GLOBEIMUNON Appoints Dr. Patrick Ott to its Scientific Advisory..
28/9/202314:30GLOBEIMUNON Reports Interim Progression-Free Survival and Overall..
26/9/202314:30GLOBEIMUNON Releases Enterprise Video Highlighting the Company’s..
13/9/202314:30GLOBEIMUNON Reminds Investors of its Virtual R&D Day Tomorrow at..
07/9/202322:30GLOBEIMUNON to Host Virtual R&D Day on September 14th Beginning..
05/9/202314:30GLOBEIMUNON to Participate in the H.C. Wainwright Global..
24/8/202322:05GLOBEIMUNON Enters into CRADA for Preclinical Studies of PlaCCine..
14/8/202314:30GLOBEIMUNON Expands Scientific Advisory Board with the Addition..
10/8/202314:00GLOBEIMUNON Reports Second Quarter 2023 Financial Results and..
07/8/202314:30GLOBEPreclinical Data Showing Strong Immunogenicity and..
03/8/202314:30GLOBEIMUNON to Hold Second Quarter 2023 Financial Results and..
27/6/202318:00GLOBEIMUNON Unveils New Manufacturing Capabilities at..
26/6/202323:00GLOBEImunon Reports Inducement Grants under NASDQ Listing Rule..
12/6/202314:30GLOBEIMUNON CEO to Discuss Company’s Novel Non-viral DNA Therapy..
08/6/202314:30GLOBEIMUNON’s CEO Presents Business Overview to Investors and..
30/5/202314:00GLOBEIMUNON Presents PlaCCine Preclinical Data at the 2023..
11/5/202314:00GLOBEIMUNON Reports First Quarter 2023 Financial Results and..

Dernières Valeurs Consultées

NASDAQ
IMNN
Imunon
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés